ClinicalTrials.gg
RecruitingNCT05629026LYMPHODYSUpdated Dec 31, 2025

Study of Lymphatic Dysfunction in Primary and Secondary Lymphedema

An interventional study of Micro-biopsies in Lymphedema, sponsored by University Hospital, Toulouse. Recruiting at 1 site in France. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-12-31.

Sponsored by University Hospital, Toulouse · Not applicable, Interventional, and Basic science

How we know

From the registry’s dates

  • Primary completion was expected by Feb 2026, 9 months ago, but the record still lists the study as recruiting.
  • Started Feb 2024; still recruiting 2 years 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Non-randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 29 studies in Lymphedema with a site in France — 6 open to participants now, 6 under way, none of them phase 3. Lymphedema · France.

Planned enrollment
9th of 18
60 · median 53
Started
2024
the only one that year
No phase
17 of 29
5 open now
Registered
24th of 29
by date
Lead sponsor
2 of 29
University Hospital, Toulouse

Among the 29 studies in Lymphedema with a site in France, this one is the 9th largest by planned enrollment of the 18 interventional ones that give a count, is the only one that started in 2024, is one of 17 with no phase, and was the 24th registered.

Lymphedema

529 studies on the registry are indexed under Lymphedema; 129 are open to participants now.

Browse Lymphedema studies →

Open to participants now

6 of the 29 studies in Lymphedema with a site in France are open now. Recruiting first, the newest first:

All 6 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 84 Lymphedema studies recruiting now, 46 (55%) set no upper age limit and 21 (25%) stop at 75 or younger; 5 take children under 18; 12 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 29 studies in Lymphedema with a site in France, or all of them as a file.
02

Study summary

Lymphedema is a disorder of the lymphatic vascular system characterized by impaired lymphatic return and swelling of the extremities and accumulation of undrained interstitial fluid/lymph that results in fibrosis and adipose tissue deposition in the affected area. It can be an inherited condition (primary lymphedema) or occurs after cancer surgery and lymph node removal (secondary lymphedema). It causes a significant morbidity and is a common disabling disease affecting more than 200 million people worldwide, however there is no curative treatment for primary or secondary lymphedema.

Read the detailed description

Primary lymphedema is an inherited condition whereas secondary lymphedema develops after cancer treatments. Despite common phenotype, a molecular and histological comparison of these two pathologies has never been performed. Primary lymphedema is associated with heterozygous inactivating mutations of the gene encoding vascular endothelial growth factor C and D receptor (VEGFR-3). Primary lymphedema is rare, affecting 1 in 100,000 individuals. Secondary lymphedema is the most common cause of the disease and affects more than 200 million people worldwide.

Secondary lymphedema occurs months, sometimes years after cancer surgery suggesting that lymphedema is not only a side effect of the surgery, but involves modifications of the lymphatic architecture as well as its microenvironment, in particular adipose tissue that accumulates in the limb.

There is no cure for lymphedema because of the lack of identified therapeutic strategies able to restore collecting lymphatic draining function in the arm or in the leg. The goal will be to establish if these pathologies which possess a common denomination exhibit a similar gene expression.

03

Conditions studied

  • Lymphedema

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients in who developed primary lymphedema or secondary lymphedema after breast cancer treatment.
  2. Male and female over the age of 18 and under 75.
  3. Patient affiliated to a social security scheme in France.
  4. Patient having signed prior to inclusion in the study and prior to any specific procedure for the study.
  5. Patients with no recidive > 3 years after cancer surgery.
  6. Patients with \<35.
  7. Patient enrolled in a care pathway for the management of their lymphedema (medical and educational care).
  8. Patients wearing a compression orthosis on the limb with lymphedema.

Exclusion criteria

Exclusion Criteria:

  1. Patients with strong suspicion or with active bacterial or fungal infection.
  2. Patient with venous insufficiency associated with lymphedema.
  3. Patient with a history of deep venous thrombosis on the limb with lymphedema.
  4. History of chronic inflammatory disease.
  5. Active neoplasia during parallel management.
  6. Patient already included in another therapeutic trial.
  7. Pregnant or breastfeeding woman.
  8. cancer.
  9. Bilateral breast cancer.
  10. Obliterative arterial disease.
  11. Multiple erysipelas.
  12. Active smoking (delayed healing).
  13. Medicines that may promote delayed healing ( therapy, ).
  14. Medication that thins the blood (aspirin and antiplatelet agent, anti-coagulant).
  15. Betadine allergy.
  16. Patient under guardianship or trusteeship, persons placed under the protection of justice
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    primary lymphoedema

    patients with primary lymphoedema

    Procedure: Micro-biopsies

  • Experimental
    secondary lymphoedema

    patients with secondary lymphoedema

    Procedure: Micro-biopsies

Interventions

  • ProcedureMicro-biopsies

    Two micro-biopsies of limb tissue will be carried out, one on the lymphedema and one in the upper limb not affected.

06

What researchers measure

Primary outcomes

  1. Number of RNA transcripts between lymphoedema limb and healthy limb

    The gene expression profile of primary and secondary lymphedema will be determined by high-throughput RNA sequencing (RNAseq) or next-generation sequencing (NGS). It is a molecular methodology that allows the rapid sequencing of thousands to millions of RNA molecules simultaneously, determining the unique and specific order of nucleic acid bases. It is a random sequencing of the whole transcriptome which is used to identify and quantify the RNA resulting from the transcription of the genome at a given time.

    Time frame: Day 1

Secondary outcomes

  1. LYVE-1 expression in primary and secondary lymphedema by immuno-histology

    LYVE-1 (lymphatic vessel endothelial hyaluronan receptor-1) will be determined from immunodetection and staining performed on paraffin sections of lymphedema tissue in comparison with healthy tissue

    Time frame: Day 1

  2. Podoplanin expression in primary and secondary lymphedema by immuno-histology

    Podoplanin expression will be determined from immunodetection and staining performed on paraffin sections of lymphedema tissue in comparison with healthy tissue

    Time frame: Day 1

  3. Chromatography analysis of Lipids in adipose tissues from primary and secondary lymphoedema

    To describe lipid profile in adipose tissues from primary and secondary lymphoedema, in comparison to the healthy limb by chromatography analysis expressed in pg lipid/mg protein.

    Time frame: Day 1

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2024 (actual). Primary completion is estimated for Feb 2026, 24 months after the start.

Of 175 non-industry interventional studies with no phase under Lymphedema, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 68. This study's planned 24 months is below that.

Counting every sponsor, half of 197 studies reached it within 25 months; a quarter within 11 and three quarters within 64.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 3, 2022
First posted
Nov 29, 2022
StartActual
Feb 21, 2024
Primary completionEst.
Feb 2026
CompletionEst.
Feb 2026
Last update
Dec 31, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 31, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05629026
Responsible party
Sponsor
First posted
Nov 29, 2022
Start date
Feb 21, 2024
Primary completion
Feb 2026 (estimated)
Completion
Feb 2026 (estimated)
Last update
Dec 31, 2025

Study contacts

Julie MALLOIZEL-DELAUNAY, MD
Contact
malloizel-delaunay.j@chu-toulouse.fr
+33 (0)5 61 32 30 33
Charline DAGUZAN
Contact
daguzan.c@chu-toulouse.fr
+33 (0)5 61 77 84 99
Julie Malloizel-Delaunay, MD
principal investigator · University Hospital, Toulouse

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion